Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Prestige Brands plans changes for ex-Glaxo brands; PGT Healthcare bears early fruit for Teva; Pfizer cranks up buybacks, cost-cutting; GlaxoSmithKline core OTCs on track; more Sales & Earnings In Brief.
You may also be interested in...
Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth
Following allegations from short seller Citron Research that it operates a “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.
Nexium OTC Switch Would Face Crowded Field, Potential Questions
Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.